Our data highlight LINC00461-associated regulatory networks in GBM malignancies, including treatment resistance and cancer stemness, and provide a novel insight into targeting the HDAC6/RBP/LINC00461 axis as a therapeutic approach for patients with GBM. Here, HDAC6 is linked to glioblastoma.